Genentech, Inc. Overview
Pro stress-test →Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. A member of the Roche Group, the company has headquarters in South San Francisco, California. The organization operates with a unique dual identity: as part of the Roche portfolio while maintaining its own independent Research & Early Development group, allowing scientists to work freely and enhance innovation.
Strategic Profile
Pro stress-test →Historically regarded as the world's first biotechnology company, Genentech is advancing multiple high-impact therapeutic areas including oncology, ophthalmology, and obesity. The company is executing significant capital investments to support growth, with a $2 billion manufacturing expansion in North Carolina set to be operational by 2029 to produce next-generation treatments for metabolic conditions such as obesity. This positions Genentech as a key driver of Roche's pharmaceutical innovation agenda.
Competitive Landscape
Pro stress-test →Genentech competes in high-growth metabolic and ophthalmology markets against diversified competitors. In obesity/weight management, rivals include Novo Nordisk (GLP-1 products), Eli Lilly (oral GLP-1/GIP compounds), and Viking Therapeutics (VK2735). In ophthalmology, competitors include Novartis, Regeneron, and Apellis Pharmaceuticals in retinal disease treatment. Genentech's dual program approach (sequential GLP-1/GIP compounds, combination strategies) and integration within Roche's diagnostics/digital capabilities provide platform differentiation.
Industry Context
Genentech, Inc. operates in Biopharmaceutical drug discovery and development.
Key facts
Founded: 1976 · Headquarters: South San Francisco, US · Employees: 13,539 (July 2021) · Revenue: N/A · Market cap: N/A